RDY
DR REDDYS LABORATORIES LTD
$13.49
-0.99%
$11.4B
No data for this timeframe.
Vol
Market Cap$11.4B
Cap SizeLarge Cap
Inst. Holders6 funds
Inst. Value$320.1M
Inst. Activity1 buys / 1 sells
SEC Reports15
Recent Activity
May 19, 2026
short_volume
Short Volume: RDY — 62.2% short (0.4M / 0.6M)
Short: 367,709 | Exempt: 0 | TRF Vol: 591,596 | Short Ratio: 62.2% | Off-exchange volume (dark pool
May 18, 2026
SEC
Dr. Reddy's submitted a 6-K filing enclosing the transcript of its Q4 FY2026 earnings call held on May 12, 2026. The fil
6-K — Impact 2/10
May 18, 2026
SEC
Dr. Reddy's Laboratories filed a 6-K furnishing a schedule of upcoming analyst/institutional investor meetings from May
6-K — Impact 2/10
May 15, 2026
SEC
Dr. Reddy's launched its generic Semaglutide Injection in Canada on May 15, 2026, following Health Canada approval on Ap
6-K — Impact 6/10
Inst.
MORGAN STANLEY — ADD
8,926,051 shares ($125.3M)
Inst.
CAUSEWAY CAPITAL MANAGEMENT LLC — EXIT
0 shares ($0.00)
Apr 23, 2026
Event
Amiodarone Hydrochloride
WARNING: PULMONARY, HEPATIC and CARDIAC TOXICITY Amiodarone hydrochloride tablets is intended for us
Price Targets
Historical data — last covering-analyst action Jun 2025. No current recommendation available.
$14.09 (Jun 2025)
Current $13.50
Low $11.34
Median $13.93
High $16.62
5 analysts
$11.34
$16.62
Analyst Ratings
8Strong Buy
14Buy
10Hold
8Sell
4Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 5, 2025 | HSBC | UPGRADE | Hold → Buy |
| Nov 6, 2024 | Barclays | MAINTAIN | Overweight → Overweight |
| Jul 30, 2024 | Barclays | MAINTAIN | Overweight → Overweight |
| May 8, 2024 | Barclays | MAINTAIN | Overweight → Overweight |
| Jan 29, 2024 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $51.40 | $51.40 — $51.40 | 1 | |
| Next FY | $64.96 | $64.96 — $64.96 | 26% YoY | 1 |
Latest Reports
NEUTRAL
6-K
2/10
Dr. Reddy's submitted a 6-K filing enclosing the transcript of its Q4 FY2026 earnings call held on May 12, 2026. The fil
May 18, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's Laboratories filed a 6-K furnishing a schedule of upcoming analyst/institutional investor meetings from May
May 18, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $125.3M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $115.9M | DOUBLED |
| VANGUARD GROUP INC | $70.6M | — |
| BANK OF AMERICA CORP | $7.0M | TRIM |
| FMR LLC | $1.2M | — |
6 institutional holders with $320.1M total value (22,801,556 shares) as of 2025-Q4. Top holders: MORGAN, RENAISSANCE, VANGUARD.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 8,926,051 | $125.3M | 39.1% | ADD +41.2% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 8,255,128 | $115.9M | 36.2% | DOUBLED +382.9% |
| 3 | VANGUARD GROUP INC | 5,027,272 | $70.6M | 22.0% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 496,925 | $7.0M | 2.2% | TRIM -53.1% |
| 5 | FMR LLC | 86,742 | $1.2M | 0.4% | — |
| 6 | WELLS FARGO & COMPANY/MN | 9,438 | $132.5K | 0.0% | DOUBLED +495.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 6,322,154 | 8,926,051 | +41.2% | $125.3M | 2025-Q4 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | EXIT | 159,139 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | ADD | 4,854,849 | 6,322,154 | +30.2% | $88.4M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 869,889 | 408,041 | -53.1% | $5.7M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 8,736,296 | 4,854,849 | -44.4% | $73.0M | 2025-Q2 |
| UBS Group AG | ADD | 899,809 | 1,206,843 | +34.1% | $18.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,976,362 | 869,889 | -56.0% | $13.1M | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 17,500 | 162,463 | +828.4% | $2.1M | 2025-Q1 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | TRIM | 539,305 | 144,439 | -73.2% | $1.9M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 2,242,132 | 11,258,915 | +402.2% | $177.8M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 1,950,449 | 9,418,428 | +382.9% | $148.7M | 2024-Q4 |
| UBS Group AG | DOUBLED | 17,217 | 780,822 | +4435.2% | $12.3M | 2024-Q4 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | DOUBLED | 107,861 | 539,305 | +400.0% | $8.5M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 9,500 | 17,500 | +84.2% | $276.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,314 | 7,826 | +495.6% | $123.6K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
15 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 12 neutral. Avg impact: 3.1/10.
NEUTRAL
6-K
2/10
Dr. Reddy's submitted a 6-K filing enclosing the transcript of its Q4 FY2026 earnings call held on M
May 18, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's Laboratories filed a 6-K furnishing a schedule of upcoming analyst/institutional investo
May 18, 2026
BULLISH
6-K
6/10
Dr. Reddy's launched its generic Semaglutide Injection in Canada on May 15, 2026, following Health C
May 15, 2026
NEUTRAL
6-K
3/10
Dr. Reddy's Laboratories filed its Q4 FY26 audited financial results presentation via a 6-K on May 1
May 12, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's Laboratories filed a 6-K providing a link to the audio recording of its Q4 FY2026 earnin
May 12, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's filed a routine 6-K reporting board meeting outcomes: re-appointment of an independent d
May 12, 2026
NEUTRAL
6-K
1/10
Dr. Reddy's management will participate in investor conferences hosted by HSBC (Mumbai, May 14-15) a
May 12, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's granted 1,192,234 stock options (816,119 Indian stock options + 376,115 ADR stock option
May 11, 2026
BULLISH
6-K
6/10
Dr. Reddy's received Health Canada approval for its generic Semaglutide Injection, the first generic
Apr 29, 2026
NEUTRAL
6-K
3/10
Dr. Reddy's Laboratories announced it will release its Q4 and full year FY26 results on May 12, 2026
Apr 24, 2026
NEUTRAL
6-K
4/10
Dr. Reddy's Laboratories confirmed it has not yet received Health Canada approval for its Semaglutid
Apr 24, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's Laboratories announced that its Board of Directors will consider recommending a final di
Apr 16, 2026
NEUTRAL
6-K
3/10
Dr. Reddy's Laboratories announced the sale of its wholly owned subsidiary, Svaas Wellness Limited,
Apr 8, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's Laboratories issued 3,675 equity shares on March 26, 2026, following the exercise of sto
Mar 26, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jun 2025): 50% buy across 44 analysts — 8 strong buy, 14 buy, 10 hold, 8 sell, 4 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jun 2025. No current recommendation available.
$14.09 mean target (Jun 2025)
$11.34 Low
$16.62 High
| Metric | Value |
|---|---|
| Current Price | $13.50 |
| Target Low | $11.34 |
| Target Mean | $14.09 |
| Target Median | $13.93 |
| Target High | $16.62 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $80.9B | -5.3% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $88.1B | 0.0% | — |
| Current FY 2027-03-31 |
$51.40 | $51.40 | $51.40 | — | — | 0↑ 1↓ | $357.1B | 6.3% | 1 |
| Next FY 2028-03-31 |
$64.96 | $64.96 | $64.96 | 26.4% | — | 0↑ 1↓ | $394.0B | 10.3% | 1 |
11 analyst firms have rated this stock: 8 upgrades, 8 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 5, 2025 | HSBC | UPGRADE | Hold | Buy |
| Nov 6, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Jul 30, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| May 8, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 29, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Jun 1, 2023 | Barclays | MAINTAIN | Overweight | Overweight |
| Oct 31, 2022 | Barclays | MAINTAIN | — | Overweight |
| Oct 25, 2022 | Barclays | MAINTAIN | — | Overweight |
| Sep 12, 2022 | Barclays | MAINTAIN | — | Overweight |
| Jul 25, 2022 | Barclays | MAINTAIN | — | Overweight |
| May 24, 2022 | Barclays | MAINTAIN | — | Overweight |
| Nov 1, 2021 | Barclays | MAINTAIN | — | Overweight |
| Feb 2, 2021 | Barclays | UPGRADE | Equal-Weight | Overweight |
| Jan 28, 2020 | CLSA | DOWNGRADE | Buy | Outperform |
| Jan 9, 2020 | Citigroup | UPGRADE | Sell | Buy |
| Nov 4, 2019 | B of A Securities | DOWNGRADE | Buy | Neutral |
| Sep 4, 2019 | Credit Suisse | UPGRADE | Underperform | Outperform |
| Jun 11, 2019 | Barclays | INITIATE | — | Equal-Weight |
| May 20, 2019 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Nov 1, 2017 | Jefferies | MAINTAIN | — | Underperform |
| Sep 21, 2017 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Jul 27, 2016 | HSBC | DOWNGRADE | Hold | Reduce |
| Jul 27, 2016 | Jefferies | DOWNGRADE | Hold | Underperform |
| Jul 26, 2016 | Credit Suisse | DOWNGRADE | Neutral | Underweight |
| May 2, 2016 | Goldman Sachs | INITIATE | — | Neutral |
| Feb 10, 2016 | CLSA | UPGRADE | Underperform | Buy |
| Dec 2, 2015 | Deutsche Bank | INITIATE | — | Sell |
| Feb 15, 2013 | B of A Securities | DOWNGRADE | Buy | Neutral |
| Dec 12, 2012 | Credit Suisse | UPGRADE | Neutral | Outperform |
| Jun 28, 2012 | Anand Rathi | UPGRADE | Hold | Buy |
| Feb 7, 2012 | Credit Suisse | DOWNGRADE | Buy | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 8 | 14 | 10 | 8 | 4 | 50% | |
| Apr 1, 2026 | 9 | 14 | 11 | 7 | 4 | 51% | |
| Mar 1, 2026 | 9 | 13 | 11 | 7 | 4 | 50% | |
| Feb 1, 2026 | 9 | 13 | 11 | 7 | 4 | 50% | |
| Jan 1, 2026 | 5 | 8 | 14 | 11 | 7 | 29% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
Clinical Trial
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Phase Phase 2 — COMPLETED
May 19, 2026
short_volume
Short Volume: RDY — 62.2% short (0.4M / 0.6M)
Short: 367,709 | Exempt: 0 | TRF Vol: 591,596 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
Clinical Trial
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase Phase 2 — TERMINATED
May 14, 2026
short_volume
Short Volume: RDY — 60.6% short (0.8M / 1.4M)
Short: 837,351 | Exempt: 618 | TRF Vol: 1,382,649 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
Clinical Trial
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
Phase Phase 2 — TERMINATED
May 13, 2026
Clinical Trial
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
Phase Phase 2 — COMPLETED
May 13, 2026
short_volume
Short Volume: RDY — 72.2% short (1.3M / 1.8M)
Short: 1,317,650 | Exempt: 5,360 | TRF Vol: 1,824,458 | Short Ratio: 72.2% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: RDY — 88.1% short (1.8M / 2.0M)
Short: 1,761,799 | Exempt: 0 | TRF Vol: 1,999,198 | Short Ratio: 88.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: RDY — 86.8% short (1.2M / 1.4M)
Short: 1,186,296 | Exempt: 0 | TRF Vol: 1,366,112 | Short Ratio: 86.8% | Off-exchange volume (dark pool + OTC)
May 8, 2026
Clinical Trial
Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy
Phase Phase 2 — TERMINATED
May 8, 2026
short_volume
Short Volume: RDY — 88.9% short (0.8M / 0.9M)
Short: 773,129 | Exempt: 0 | TRF Vol: 869,234 | Short Ratio: 88.9% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: RDY — 90.7% short (1.0M / 1.1M)
Short: 952,506 | Exempt: 171 | TRF Vol: 1,050,586 | Short Ratio: 90.7% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: RDY — 90.3% short (1.6M / 1.7M)
Short: 1,558,423 | Exempt: 0 | TRF Vol: 1,725,677 | Short Ratio: 90.3% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: RDY — 80.8% short (0.6M / 0.7M)
Short: 582,399 | Exempt: 0 | TRF Vol: 720,510 | Short Ratio: 80.8% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: RDY — 77.0% short (0.7M / 1.0M)
Short: 740,079 | Exempt: 325 | TRF Vol: 960,684 | Short Ratio: 77.0% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_volume
Short Volume: RDY — 84.9% short (0.9M / 1.0M)
Short: 886,762 | Exempt: 0 | TRF Vol: 1,044,949 | Short Ratio: 84.9% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
short_volume
Short Volume: RDY — 75.9% short (0.7M / 0.9M)
Short: 666,972 | Exempt: 0 | TRF Vol: 879,190 | Short Ratio: 75.9% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: RDY — 78.9% short (0.9M / 1.1M)
Short: 887,670 | Exempt: 47 | TRF Vol: 1,124,833 | Short Ratio: 78.9% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: RDY — 62.6% short (0.7M / 1.0M)
Short: 652,051 | Exempt: 2,930 | TRF Vol: 1,041,235 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: RDY — 57.4% short (0.3M / 0.5M)
Short: 310,456 | Exempt: 900 | TRF Vol: 541,057 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
FDA
Amiodarone Hydrochloride
WARNING: PULMONARY, HEPATIC and CARDIAC TOXICITY Amiodarone hydrochloride tablets is intended for use only in patients with the indicated life-threate
Mar 17, 2026
FDA
Fluoxetine
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adul
Sep 7, 2022
FDA
VIGABATRIN
Jan 14, 2019
FDA
VIGABATRIN
Nov 20, 2018
FDA
VIGABATRIN